Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Other Non Operating Income: 2022-2025

Historic Other Non Operating Income for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $4.4 million.

  • Praxis Precision Medicines' Other Non Operating Income fell 10.15% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 54.45%. This contributed to the annual value of $17.3 million for FY2024, which is 460.27% up from last year.
  • Praxis Precision Medicines' Other Non Operating Income amounted to $4.4 million in Q3 2025, which was down 10.43% from $4.9 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Other Non Operating Income high stood at $5.4 million for Q1 2025, and its period low was $132,000 during Q1 2022.
  • For the 3-year period, Praxis Precision Medicines' Other Non Operating Income averaged around $3.2 million, with its median value being $4.4 million (2025).
  • As far as peak fluctuations go, Praxis Precision Medicines' Other Non Operating Income surged by 642.44% in 2024, and later declined by 10.15% in 2025.
  • Quarterly analysis of 4 years shows Praxis Precision Medicines' Other Non Operating Income stood at $280,000 in 2022, then spiked by 231.43% to $928,000 in 2023, then soared by 468.64% to $5.3 million in 2024, then fell by 10.15% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.9 million for Q2 2025, and $5.4 million during Q1 2025.